Clinical Trials Directory

Trials / Completed

CompletedNCT03518814

Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM)

Evaluation of the Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
Lille Catholic University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Few studies have been conducted on the quality of life of patients with stage IV melanoma. Particularly, there is no data regarding the quality of life of patients with a multimetastatic melanoma currently in remission. Then, the main objective of this study is to evaluate the quality of life from a point of view medico-psycho-social in patients with multimetastatic melanoma in remission for more than 6 months.

Detailed description

The cutaneous melanoma, (9th rank of all cancers), was until recently neglected and poorly known by the general public. The metastatic stages have dramatic rates of survival: 25% at 1 year and 2% at 5 years with a median of about 6.2 months. However, in the last ten years, the treatment of metastatic forms has undergone a real revolution. Its high metastatic potential for a very low initial tumor mass, gives evidence of a great aggressiveness. The cutaneous melanoma is resistant to the main therapeutics (chemotherapy and radiotherapy). Thanks to the emergence of immunotherapies and targeted therapies anti-RAF (Rapidly Accelerated Fibrosarcoma) and anti-MEK (Mitogen-activated Extracellular) the prognosis of patients with metastatic melanoma has considerably improved, increasing the number of "long-term survivors". However, these treatments can cause many adverse effects that can impact patients' quality of life, despite a better tolerance compared to conventional chemotherapies. To our knowledge there are no data regarding the quality of life of patients with metastatic melanoma currently in remission.For this purpose, it is necessary to obtain solid data using validated questionnaires. Thus, we have chosen to evaluate quality of life using specific questionnaires to better understand patients' expectations, their difficulties, and then to improve the relationship between the patient and the physician.

Conditions

Interventions

TypeNameDescription
OTHERQuestionnairesFACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire

Timeline

Start date
2018-04-09
Primary completion
2018-06-05
Completion
2018-06-05
First posted
2018-05-08
Last updated
2018-07-19

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03518814. Inclusion in this directory is not an endorsement.